Intrexon (NYSE:XON) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other equities analysts have also issued research reports about the stock. Bank of America lowered shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target for the company. in a research report on Monday, July 16th. Stifel Nicolaus initiated coverage on shares of Intrexon in a research report on Tuesday, July 17th. They set a “buy” rating and a $72.00 price target for the company. Finally, Zacks Investment Research lowered shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Monday, July 16th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Intrexon presently has an average rating of “Hold” and an average target price of $33.14.

Shares of NYSE:XON traded up $0.14 during trading on Monday, reaching $14.50. The stock had a trading volume of 644,800 shares, compared to its average volume of 1,549,182. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 1.93. The firm has a market cap of $1.95 billion, a PE ratio of -15.76 and a beta of 1.08. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $20.67.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). The firm had revenue of $45.30 million during the quarter, compared to analyst estimates of $51.70 million. Intrexon had a negative net margin of 82.17% and a negative return on equity of 17.22%. During the same period in the prior year, the firm earned ($0.16) EPS. sell-side analysts expect that Intrexon will post -0.86 earnings per share for the current fiscal year.

In related news, CEO Randal J. Kirk purchased 7,479,431 shares of the company’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was purchased at an average price of $13.37 per share, with a total value of $99,999,992.47. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Helen Sabzevari sold 8,402 shares of the company’s stock in a transaction that occurred on Wednesday, July 18th. The stock was sold at an average price of $14.54, for a total transaction of $122,165.08. Following the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $363,500. The disclosure for this sale can be found here. Corporate insiders own 48.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in XON. Two Sigma Advisers LP acquired a new stake in shares of Intrexon in the fourth quarter worth $124,000. Wells Fargo & Company MN increased its position in shares of Intrexon by 46.4% in the first quarter. Wells Fargo & Company MN now owns 162,089 shares of the biotechnology company’s stock worth $2,485,000 after acquiring an additional 51,356 shares in the last quarter. Mirador Capital Partners LP acquired a new stake in shares of Intrexon in the first quarter worth $278,000. Third Security LLC increased its position in shares of Intrexon by 2.1% in the first quarter. Third Security LLC now owns 59,132,705 shares of the biotechnology company’s stock worth $906,504,000 after acquiring an additional 1,204,416 shares in the last quarter. Finally, Frontier Capital Management Co. LLC increased its position in shares of Intrexon by 90.1% in the first quarter. Frontier Capital Management Co. LLC now owns 525,172 shares of the biotechnology company’s stock worth $8,051,000 after acquiring an additional 248,888 shares in the last quarter. 82.16% of the stock is owned by institutional investors.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: Book Value Of Equity Per Share – BVPS Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.